The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.
 
Jonathan W. Riess
Consulting or Advisory Role - Abbvie; Biodesix; Celgene; Loxo; Medtronic; Spectrum Pharmaceuticals; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Susan G. Groshen
No Relationships to Disclose
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Euclises; Exelixis; Guardant Health; Loxo; Precision Health Economics; Seagen; Takeda; Tesaro
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Loxo (Inst); Molecular Partners (Inst); Pfizer (Inst); Seagen (Inst); Xcovery (Inst); Zeno Pharmaceuticals (Inst)
 
Heather A. Wakelee
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - AstraZeneca
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Geoffrey R. Oxnard
Honoraria - Bio-Rad; Chugai Pharma; Guardant Health; Sysmex
Consulting or Advisory Role - AstraZeneca; DropWorks; GRAIL; Ignyta; Inivata; LOXO; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Sukhmani Kaur Padda
Consulting or Advisory Role - Abbvie; AstraZeneca; G1 Therapeutics; Janssen
Research Funding - Bayer (Inst); EpicentRx (Inst); Forty Seven (Inst)
 
Marianna Koczywas
Speakers' Bureau - AstraZeneca
 
Zofia Piotrowska
Consulting or Advisory Role - Abbvie; ARIAD/Takeda; AstraZeneca; Guardant Health; Immunogen; Immunogen; Novartis; Spectrum Pharmaceuticals
Research Funding - ARIAD/Takeda (Inst); AstraZeneca (Inst); Guardant Health (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; AstraZeneca
 
Lynette M. Sholl
Consulting or Advisory Role - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - Gfk; Research to Practice
 
Cloud P. Paweletz
Honoraria - AstraZeneca; Bio-Rad
Consulting or Advisory Role - DropWorks
Travel, Accommodations, Expenses - AstraZeneca
 
Christie J. Lau
No Relationships to Disclose
 
Jill Kolesar
Stock and Other Ownership Interests - Helix Diagnostics
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - AstraZeneca; Guardant Health; Pfizer
Research Funding - Boehringer Ingelheim
 
Jeffrey Moscow
No Relationships to Disclose
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Araxes Pharma; AstraZeneca; Biocartis; Boehringer Ingelheim; Chugai Pharma; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; CellMax Life; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Nektar; Pfizer; Turnstone Bio
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Polaris (Inst); TRACON Pharma (Inst)
 
Edward M. Newman
No Relationships to Disclose
 
David R. Gandara
No Relationships to Disclose